Propanc Biopharma Stock Soars 254.7% on Nasdaq Uplisting

On August 18, 2025, Propanc Biopharma's stock surged by 254.7% in pre-market trading, marking a significant milestone for the biopharmaceutical company.

Propanc Biopharma recently announced its successful uplisting to the Nasdaq, opening at $4.00 per share. This move is expected to enhance the company's visibility and liquidity, potentially attracting more investors.

The company has also been actively engaged in fundraising efforts, announcing a $4 million public offering. This capital infusion is likely aimed at supporting ongoing research and development initiatives, which could drive future growth and innovation.

Despite recent volatility, Propanc Biopharma's stock has shown resilience, with a notable increase of 12.41% to $3.35 in recent trading sessions. This positive momentum reflects investor confidence in the company's strategic direction and potential for long-term success.